HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians

被引:16
|
作者
Ingiliz, Patrick [1 ]
Rockstroh, Juergen K. [2 ]
机构
[1] Med Ctr Infect Dis Berlin, Berlin, Germany
[2] Univ Bonn, Dept Med 1, Bonn, Germany
关键词
boceprevir; DAA; HIV-HCV co-infection; liver fibrosis; telaprevir; HEPATITIS-C-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; GENOTYPE; INFECTION; LIVER FIBROSIS; PLUS RIBAVIRIN; TRANSIENT ELASTOGRAPHY; PEGYLATED INTERFERON; POSITIVE INDIVIDUALS; THERAPY; BIOPSY;
D O I
10.1111/j.1478-3231.2012.02796.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
With the licensing of the first hepatitis C (HCV) protease inhibitors (PI), telaprevir (TVR) and boceprevir (BOC), cure rates for chronic HCV infection will substantially improve. Human immunodeficiency virus-chronic hepatitis C (HIV-HCV) co-infected patients are in urgent need for these new drugs, because they are facing both severe liver disease and lower response rates than HCV monoinfected patients. The currently available efficacy data are however, limited to two phase II trials. Fortunately, TVR and BOC appear to be able to improve cure rates in co-infected patients. A major challenge for clinicians will be the management of drug-drug interactions of antiretroviral drugs and new PI. As HCV PI are also metabolized by the cytochrome P450 3A4 system interactions are probable as well with non-nucleoside reverse transcriptase inhibitors as with HIV PI. To our knowledge, TVR can only be safely used with one protease inhibitor, boosted atazanavir, and also with efavirenz (EFV), although this combination requires TVR dose adjustments. Boceprevir should not be combined with HIV PI and should not be combined with EFV. The approval of TVR and BOC will create new chances of cure also for HIV-HCV co-infected patients. However, the decision who to treat or not has to be taken carefully on the basis of fibrosis stage and previous treatment outcomes. In addition, HIV therapy needs to be optimized according to the available drug-drug interaction data.
引用
收藏
页码:1194 / 1199
页数:6
相关论文
共 50 条
  • [31] HCV treatment in children and young adults with HIV/HCV co-infection in Europe
    Turkova, Anna
    Giacomet, Vania
    Goetghebuer, Tessa
    Miloenko, Milana
    Nicolini, Laura Ambra
    Noguera-Julian, Antoni
    Rojo, Pablo
    Volokha, Alla
    Indolfi, Giuseppe
    Giaquinto, Carlo
    Thorne, Claire
    JOURNAL OF VIRUS ERADICATION, 2015, 1 (03) : 179 - 184
  • [32] UNTREATED HCV IN HIV/HCV CO-INFECTION; DATA FROM THE TRIO NETWORK
    Jayaweera, Dushyantha
    Althoff, Keri
    Eron, Joseph J.
    Huhn, Gregory
    Milligan, Scott
    Mills, Anthony
    Moyle, Graeme
    Santiago, Steven
    Sax, Paul
    Voskuhl, Gene
    Wyles, David L.
    Elion, Rick
    GASTROENTEROLOGY, 2018, 154 (06) : S1189 - S1189
  • [33] Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel
    Soriano, V
    Sulkowski, M
    Bergin, C
    Hatzakis, A
    Cacoub, P
    Katlama, C
    Cargnel, A
    Mauss, S
    Dieterich, D
    Moreno, S
    Ferrari, C
    Poynard, T
    AIDS, 2002, 16 (06) : 813 - 828
  • [34] Untreated HCV in HIV/HCV co-infection: Data from the TRIO network
    Jayaweera, D.
    Althoff, K.
    Eron, J.
    Huhn, G.
    Milligan, S.
    Mills, A.
    Moyle, G.
    Santiago, S.
    Sax, P.
    Voskuhl, G.
    Wyles, D.
    Elion, R.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S261 - S261
  • [35] RANTES (-403 G→A) promoter polymorphism in HCV and HIV/HCV co-infection
    Ahlenstiel, G
    Iwan, A
    Brackmann, HH
    Kupfer, B
    Matz, B
    Sauerbruch, T
    Spengler, U
    Woitas, RP
    JOURNAL OF HEPATOLOGY, 2003, 38 : 108 - 108
  • [36] HIV replication is associated with increased severity of liver biopsy changes in HIV-HBV and HIV-HCV co-infection
    Audsley, Jennifer
    du Cros, Philipp
    Goodman, Zachary
    McLean, Catriona
    Mijch, Anne
    Lewin, Sharon R.
    Sasadeusz, Joe
    JOURNAL OF MEDICAL VIROLOGY, 2012, 84 (07) : 993 - 1001
  • [37] Markers of Intestinal Enterocyte Injury and Systemic Inflammation in HIV, HCV & HIV/HCV co-infection
    Wurcel, Alysse G.
    Grasberger, Paula
    Paulus, Jessica K.
    Masse, Gina
    Wanke, Christine
    Knox, Tamsin A.
    HEPATOLOGY, 2014, 60 : 1087A - 1087A
  • [38] HIV/HCV Co-infection: Overcoming Barriers to Treatment
    Gross, Chloe
    Akoth, Elizabeth
    Price, Angie
    Kattakuzhy, Sarah
    Silk, Rachel
    Rosenthal, Elana
    JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE, 2016, 27 (04): : 524 - 529
  • [39] Treatment of HIV/HCV co-infection in the DAA era
    Rockstroh, J. K.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 : S20 - S21
  • [40] Epidemiology of HIV, HBV and HCV co-infection in Israel
    Olshtain-Pops, K.
    Bennachum, A.
    Safadi, R.
    HIV MEDICINE, 2019, 20 : 297 - 298